Education
About Us
Working with TipRanks
Follow Us
InspireMD (NSPR)
NASDAQ:NSPR
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.21Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: -5.38%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong revenue growth and clinical trial success for CGuard products, alongside anticipated US market expansion. However, increased operating expenses, decreased gross profit margins, and a higher net loss create financial challenges. The sentiment reflects cautious optimism with significant expectations from the US market entry.Company Guidance
During InspireMD's fourth quarter 2024 earnings call, the company reported a new quarterly high for CGuard revenue at $1.95 million, reflecting a 10.6% year-over-year growth, with full-year revenue reaching $7 million. The company sold 3,512 CGuard stents in Q4 and 12,100 units for the year, contributing to over 60,000 implants sold to date. InspireMD anticipates a US approval and launch of CGuard Prime in the first half of 2025, projecting potential Q4 US market revenue of over $16 million if the same number of stents were sold domestically. The company aims to expand its presence in the US market upon approval, backed by a robust commercial and operational strategy. For the full year 2024, total revenue increased by 13% to $7 million, while gross profit decreased due to higher costs of goods sold, driven by increased material and labor expenses. Total operating expenses rose by 52.5% to $35 million, mainly due to increased salaries and share-based compensation for the expected US market entry. The net loss for 2024 was $32 million, compared to $19.9 million in 2023. The company holds $34.7 million in cash and marketable securities as of December 31, 2024. While InspireMD did not provide forward-looking revenue guidance, they remain optimistic about their growth trajectory, especially following potential FDA approval.Record CGuard Revenue
CGuard revenue reached a new quarterly high of $1.95 million in Q4 2024, reflecting a 10.6% growth year-over-year, with $7 million in revenue for the full year 2024, translating to 13% growth compared to 2023.
CGuard Prime US Market Entry
Anticipated US approval and launch of CGuard Prime in the first half of 2025, with potential revenue of over $16 million if Q4 sales were in the US market.
Strong Clinical Trial Results
CGUARDIANS trial results showed a major adverse events rate of just 0.95% through 30 days and 1.95% through 12 months post-procedure, the lowest ever reported in a pivotal study of carotid stent or embolic protection device.
Strategic US Headquarters
New headquarters in Miami, Florida, to support the anticipated US launch and commercialization of CGuard Prime.
---
NSPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NSPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $2.79 | $2.81 | +0.72% |
| Nov 12, 2024 | $2.46 | $2.38 | -3.25% |
| Aug 06, 2024 | $2.96 | $2.98 | +0.68% |
| May 14, 2024 | $2.40 | $2.38 | -0.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does InspireMD (NSPR) report earnings?
InspireMD (NSPR) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is InspireMD (NSPR) earnings time?
InspireMD (NSPR) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NSPR EPS forecast?
NSPR EPS forecast for the fiscal quarter 2025 (Q1) is -0.2.
---